Maravai Lifesciences Holdings (DE:MAR)
FRANKFURT:MAR
Total Valuation
Maravai Lifesciences Holdings has a market cap or net worth of €1.13B. The enterprise value is €1.20B.
Market Cap€1.13B
Enterprise Value€1.20B
Share Statistics
Maravai Lifesciences Holdings has 147,506,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding147,506,160
Owned by Insiders4.54%
Owned by Institutions45.35%
Financial Efficiency
Maravai Lifesciences Holdings’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -0.91%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-0.91%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee325.86K
Profits Per Employee-404.85K
Employee Count570
Asset Turnover0.24
Inventory Turnover3.76
Valuation Ratios
The current PE Ratio of Maravai Lifesciences Holdings is ―. Maravai Lifesciences Holdings’s PEG ratio is 0.27.
PE Ratio―
PS Ratio2.54
PB Ratio2.22
Price to Fair Value2.22
Price to FCF-6.67
Price to Operating Cash Flow-18.67
PEG Ratio0.27
Income Statement
In the last 12 months, Maravai Lifesciences Holdings had revenue of 185.74M and earned -130.77M in profits. Earnings per share was -0.91.
Revenue185.74M
Gross Profit33.39M
Operating Income-6.74M
Pretax Income-234.97M
Net Income-130.77M
EBITDA-147.11M
Earnings Per Share (EPS)-0.91
Cash Flow
In the last 12 months, operating cash flow was -39.52M and capital expenditures -12.35M, giving a free cash flow of -51.87M billion.
Operating Cash Flow-39.52M
Free Cash Flow-51.87M
Free Cash Flow per Share-0.35
Dividends & Yields
Maravai Lifesciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change120.30%
50-Day Moving Average3.29
200-Day Moving Average2.89
Relative Strength Index (RSI)74.66
Average Volume (3m)66.00
Important Dates
Maravai Lifesciences Holdings upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Maravai Lifesciences Holdings as a current ratio of 6.60, with Debt / Equity ratio of 16.69%
Current Ratio6.60
Quick Ratio5.69
Debt to Market Cap0.04
Net Debt to EBITDA1.23
Interest Coverage Ratio-0.25
Taxes
In the past 12 months, Maravai Lifesciences Holdings has paid -4.21M in taxes.
Income Tax-4.21M
Effective Tax Rate0.02
Enterprise Valuation
Maravai Lifesciences Holdings EV to EBITDA ratio is -4.87, with an EV/FCF ratio of -10.13.
EV to Sales3.86
EV to EBITDA-4.87
EV to Free Cash Flow-10.13
EV to Operating Cash Flow-12.44
Balance Sheet
Maravai Lifesciences Holdings has €165.92M in cash and marketable securities with €35.31M in debt, giving a net cash position of €130.61M billion.
Cash & Marketable Securities€165.92M
Total Debt€35.31M
Net Cash€130.61M
Net Cash Per Share€0.89
Tangible Book Value Per Share€0.63
Margins
Gross margin is 29.00%, with operating margin of -3.63%, and net profit margin of -70.41%.
Gross Margin29.00%
Operating Margin-3.63%
Pretax Margin-126.50%
Net Profit Margin-70.41%
EBITDA Margin-79.20%
EBIT Margin-111.97%
Analyst Forecast
The average price target for Maravai Lifesciences Holdings is €4.88, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€4.88
Price Target Upside71.78% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast-21.50%
EPS Growth Forecast40.91%